Precipio Adds Substantial Pathology Customer to its Diagnostic Services Division
May 04, 2023 13:00 ET
|
Precipio, Inc.
NEW HAVEN, Conn., May 04, 2023 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO) announces another agreement with a new pathology services customer to utilize...
Precipio Signs Another HemeScreen™ Customer
May 04, 2023 10:00 ET
|
Precipio, Inc.
NEW HAVEN, Conn., May 04, 2023 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO) announces another agreement with a new customer to bring HemeScreen™ technology...
Precipio Granted 180-day Extension From NASDAQ To Regain Compliance
April 27, 2023 17:00 ET
|
Precipio, Inc.
NEW HAVEN, Conn., April 27, 2023 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO), announces notification by the NASDAQ Stock Market that the Company has been...
Precipio Unaudited Q1-2023 Product Revenues Exceed The Two Prior Quarters (Q3+Q4 of 2022) Combined
April 19, 2023 11:00 ET
|
Precipio, Inc.
NEW HAVEN, Conn., April 19, 2023 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO), announces that Q1-2023 product revenues have surpassed product revenues...
Precipio Announces 2022 Fourth Quarter and Year-End Shareholder Update Call
March 28, 2023 17:00 ET
|
Precipio, Inc.
NEW HAVEN, Conn., March 28, 2023 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO), will be hosting its Q4-2022 and year end shareholder update call on Monday,...
Precipio Ships First IV-Cell® Order to Major US Healthcare System
March 21, 2023 10:30 ET
|
Precipio, Inc.
NEW HAVEN, Conn., March 21, 2023 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO) delivered its first order of IV-Cell®, the Company’s proprietary cytogenetics...
CORRECTION -- Precipio continues to sign up and onboard HemeScreen™ customers
March 07, 2023 12:49 ET
|
Precipio, Inc.
NEW HAVEN, Conn., March 07, 2023 (GLOBE NEWSWIRE) -- In a release issued under the same headline earlier today by Precipio, Inc. (NASDAQ: PRPO), please note that the 5th paragraph should read...
Precipio continues to sign up and onboard HemeScreen™ customers
March 07, 2023 12:00 ET
|
Precipio, Inc.
NEW HAVEN, Conn., March 07, 2023 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO) continues to convert its sales pipeline into HemeScreen customers, with an...
ThermoFisher Salesforce Votes Precipio’s HemeScreen® as “Best New Product”
February 14, 2023 11:44 ET
|
Precipio, Inc.
NEW HAVEN, Conn., Feb. 14, 2023 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO) was recognized at ThermoFisher’s National Sales Meeting for the development and...
Precipio Signs Another Major HemeScreen™ Customer
January 11, 2023 10:00 ET
|
Precipio, Inc.
NEW HAVEN, Conn., Jan. 11, 2023 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO) announced another 4-year agreement with a new customer to bring HemeScreen™...